TTD Drug ID: DCL000007

Drug Information
Name	SNS-032
Synonyms	CID3025986; S1145_Selleck; BMS-387032; Kinome_3820; AC-5242; I09-1579; CID6918586; LS-186036; BMS-387032, SNS-032; N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; SNS-032; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; (2R,3R)-2,3-dihydroxybutanedioic acid; MolPort-005-942-660; 345627-80-7; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; AC1OCFM7; AC1MHGD4; CHEMBL296468; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); 4-Piperidinecarboxamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-; BMS-387072
Company	Sunesis/Bristol Myers Squibb
Indication	B-lymphoid malignancies and advanced solid tumours			Phase I
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
Therapeutic Class	Antineoplastic Agents
PubChem Compound ID	CID 3025986.
PubChem Substance ID	SID 3820791.
ClinicalTrials.gov	NCT00446342;
Target	Cell division protein kinase 2			Inhibitor	[1][2]
	Cell division protein kinase 2			Multitarget	[1][2]
	Cell division protein kinase 7			Inhibitor	[1][2]
	Cell division protein kinase 7			Multitarget	[1][2]
	Cell division protein kinase 9			Inhibitor	[1][2]
	Cell division protein kinase 9			Multitarget	[1][2]
Ref 1	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. Epub 2009 Feb 20. To Reference
Ref 2	Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 2009 Mar;16(2):36-43. To Reference

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.